Ahmed Salaheldin, Lundgren Jakob, Ahmed Abdulla, Rådegran Göran
Department of Clinical Sciences Lund, The Section for Cardiology, Lund University, Lund, Sweden.
The Haemodynamic Lab, The Section for Heart Failure and Valvular Disease, VO. Heart and Lung Medicine, Skåne University Hospital, Lund, Sweden.
JHLT Open. 2023 Oct 30;2:100013. doi: 10.1016/j.jhlto.2023.100013. eCollection 2023 Dec.
Inflammation and tyrosine-kinases are known mediators in the pathobiology of cardiovascular disease. Plasma biomarkers reflecting these systems may provide a noninvasive complement reflecting hemodynamics, aiding in clinical decision-making. We therefore aimed to investigate the plasma levels of vascular and inflammatory proteins, and their associations with invasive hemodynamics in advanced heart failure (HF) before, and at multiple follow-ups after heart transplantation (HT).
Using multiplex sandwich immunoassays, absolute plasma concentrations of 9 vascular and inflammatory proteins were assessed in 26 patients with advanced HF, before HT, and at 4 weeks, 6 months, and 1year after HT. Right heart catheterization hemodynamics were assessed at the time of blood sampling. Repeated measures correlations were performed to evaluate the overall intra-individual development of plasma protein levels in relation to hemodynamics' development over time.
Out of 9 proteins included initially, in advanced HF, elevated plasma levels of vascular endothelial growth factor D (VEGF-D) and soluble fms-like tyrosine kinase-1 (sFlt-1) decreased most markedly at 4 weeks ( < 0.0001), and decreased further at 6 months ( < 0.05) and at the 1 year follow-ups after-HT ( < 0.05). Over time, plasma VEGF-D correlated strongest with hemodynamic parameters including pulmonary arterial wedge pressure (PAWP) ( = 0.75, 95% bootstrapped confidence interval (CI) 0.61-0.84, < 0.0001), followed by mean right atrial pressure (MRAP) ( = 0.74, 95% CI 0.61-0.82, < 0.0001), and mean pulmonary arterial pressure (mPAP) ( = 0.74, 95% CI 0.58-0.82, < 0.0001). Plasma sFlt-1 correlated also with multiple hemodynamic parameters including PAWP ( = 0.66, 95% CI 0.58-0.79, < 0.0001), MRAP ( = 0.64, 95% CI 0.58-0.81, < 0.0001), and mPAP ( = 0.61, 95% CI 0.51-0.76, < 0.0001).
In advanced HF, elevated plasma VEGF-D and sFlt-1 levels decrease early, already within 4 weeks after HT, and further throughout the first year postoperatively. Our findings support that high plasma VEGF-D and sFlt-1 concentrations before HT are related to congestion and overall hemodynamic improvement. Plasma VEGF-D and sFlt-1 may consequently be potential noninvasive biomarkers for monitoring hemodynamic deterioration and congestion in HF, and surveillance after HT.
炎症和酪氨酸激酶是心血管疾病病理生物学中已知的介质。反映这些系统的血浆生物标志物可能提供一种反映血流动力学的非侵入性补充手段,有助于临床决策。因此,我们旨在研究晚期心力衰竭(HF)患者在心脏移植(HT)前及HT后多次随访时血管和炎症蛋白的血浆水平,以及它们与有创血流动力学的关系。
采用多重夹心免疫分析法,评估26例晚期HF患者在HT前、HT后4周、6个月和1年时9种血管和炎症蛋白的绝对血浆浓度。在采血时评估右心导管血流动力学。进行重复测量相关性分析,以评估血浆蛋白水平随时间与血流动力学变化的个体内总体发展情况。
在最初纳入的9种蛋白中,晚期HF患者血浆血管内皮生长因子D(VEGF-D)和可溶性fms样酪氨酸激酶-1(sFlt-1)水平升高,在4周时下降最为明显(<0.0001),在6个月时进一步下降(<0.05),在HT后1年随访时仍继续下降(<0.05)。随着时间推移,血浆VEGF-D与包括肺动脉楔压(PAWP)在内的血流动力学参数相关性最强(r = 0.75,95%自抽样置信区间(CI)0.61 - 0.84,<0.0001),其次是平均右心房压(MRAP)(r = 0.74,95% CI 0.61 - 0.82,<0.0001)和平均肺动脉压(mPAP)(r = 0.74,95% CI 0.58 - 0.82,<0.0001)。血浆sFlt-1也与多个血流动力学参数相关,包括PAWP(r = 0.66,95% CI 0.58 - 0.79,<0.0001)、MRAP(r = 0.64,95% CI 0.58 - 0.81,<0.0001)和mPAP(r = 0.61,95% CI 0.51 - 0.76,<0.0001)。
在晚期HF中,血浆VEGF-D和sFlt-1水平升高在HT后早期即4周内开始下降,并在术后第一年持续下降。我们的研究结果支持HT前血浆VEGF-D和sFlt-1浓度升高与充血及整体血流动力学改善有关。因此,血浆VEGF-D和sFlt-1可能是监测HF血流动力学恶化和充血以及HT后监测的潜在非侵入性生物标志物。